Acurx Pharmaceuticals, Inc. (ACXP) Financials
ACXP Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 11.0 million | 2.8 million |
| March 31, 2026 | 9.5 million | 2.5 million |
| Dec. 31, 2025 | 7.7 million | 2.4 million |
| Sept. 30, 2025 | 6.1 million | 2.5 million |
ACXP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -1.7 billion | 200.5 million |
| March 31, 2026 | -1.4 million | 258.3 million |
| Dec. 31, 2025 | -1.2 million | 375794 |
| Sept. 30, 2025 | -1.9 million | 339852 |
ACXP Net Income
No data available :(
ACXP Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 10.7 million | - | - |
| March 31, 2026 | 9.3 million | - | - |
| Dec. 31, 2025 | 7.6 billion | - | - |
| Sept. 30, 2025 | 5.9 million | - | - |
ACXP Shares Outstanding
ACXP Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 1.1 million | 1.2 million | - |
| March 31, 2026 | 3 | 341468 | 1.4 billion | - |
| Dec. 31, 2025 | - | 1.8 billion | 6.3 billion | -1.6 million |
| Sept. 30, 2025 | 1 | 429691 | 1.6 million | - |
ACXP Cost of Revenue
No data available :(
ACXP
Price: $1.44
52 week price:
Earnings Per Share: -3.79 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 73400
Market Capitalization: 6.0 million